Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 13, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 29
- −4 vs. Q2 2024
- Portfolio value
- $331.4M
- −$190.6M (−36.5%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| NGNENeurogene Inc. | COM | 1,004,291 | $42.1M | 12.7% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 2,128,773 | $24.5M | 7.4% | −343,415−13.9% | Reduced | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,910,121 | $21.4M | 6.5% | −726,743−27.6% | Reduced | History |
| EOLSEvolus, Inc. | COM | 1,170,000 | $19.0M | 5.7% | −1,281,772−52.3% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 750,000 | $17.1M | 5.1% | +250,000+50.0% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 316,000 | $16.7M | 5.0% | −158,202−33.4% | Reduced | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,299,503 | $15.0M | 4.5% | −39,065−2.9% | Reduced | History |
| DVAXDynavax Technologies Corp | COM NEW | 1,326,234 | $14.8M | 4.5% | −1,047,766−44.1% | Reduced | History |
| CNTXContext Therapeutics Inc. | COM | 6,934,982 | $13.6M | 4.1% | −484,373−6.5% | Reduced | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 3,263,672 | $13.3M | 4.0% | −1,378,569−29.7% | Reduced | History |
| ORKAOruka Therapeutics, Inc. | COM | 514,659 | $12.6M | 3.8% | +514,659 | New | History |
| MRUSMerus N.V. | COM | 250,000 | $12.5M | 3.8% | −273,288−52.2% | Reduced | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 1,000,000 | $11.9M | 3.6% | +203,120+25.5% | Added | History |
| IONSIonis Pharmaceuticals Inc | COM | 255,000 | $10.2M | 3.1% | −75,000−22.7% | Reduced | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 2,811,955 | $10.2M | 3.1% | −629,712−18.3% | Reduced | History |
| URGNUroGen Pharma Ltd. | COM | 758,786 | $9.64M | 2.9% | −2,147,473−73.9% | Reduced | History |
| OPTNOptiNose, Inc. | COM | 12,861,136 | $8.62M | 2.6% | −865,961−6.3% | Reduced | History |
| ACLXArcellx, Inc. | COMMON STOCK | 100,000 | $8.35M | 2.5% | −392,000−79.7% | Reduced | History |
| DNTHDianthus Therapeutics, Inc. | COM | 275,000 | $7.53M | 2.3% | −482,929−63.7% | Reduced | History |
| OTLKOutlook Therapeutics, Inc. | Stock | 1,293,028 | $6.90M | 2.1% | −408,482−24.0% | Reduced | History |
| JSPRJasper Therapeutics, Inc. | COM NEW | 322,380 | $6.06M | 1.8% | −79,635−19.8% | Reduced | History |
| VYGRVoyager Therapeutics, Inc. | COM | 959,953 | $5.62M | 1.7% | −641,574−40.1% | Reduced | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 500,000 | $5.22M | 1.6% | 00.0% | Unchanged | History |
| TCRXTScan Therapeutics, Inc. | COM | 1,016,375 | $5.06M | 1.5% | +75,544+8.0% | Added | History |
| UNCYUnicycive Therapeutics, Inc. | COM | 8,559,000 | $3.49M | 1.1% | +8,559,000 | New | History |
| PMNProMIS Neurosciences Inc. | COM | 2,790,698 | $3.49M | 1.1% | +2,790,698 | New | History |
| RNACCartesian Therapeutics, Inc. | COM NEW | 200,000 | $3.22M | 1.0% | +200,000 | New | History |
| VTGNVistagen Therapeutics, Inc. | COM | 674,075 | $2.03M | 0.6% | −855,263−55.9% | Reduced | History |
| CLYMClimb Bio, Inc. | COM | 248,168 | $1.26M | 0.4% | +248,168 | New | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| ACLXArcellx, Inc. | COMMON STOCK | $8.35M | – |
Sold out since Q2 2024 (9)
Positions held at the end of Q2 2024 that are gone from this filing.
| Security | Class | Shares in Q2 2024 | Value in Q2 2024 | % of portfolio in Q2 2024 | History |
|---|---|---|---|---|---|
| INSMINSMED Inc | COM PAR $.01 | 250,000 | $16.8M | 3.2% | History |
| FOLDAmicus Therapeutics, Inc. | COM | 1,495,500 | $14.8M | 2.8% | History |
| ESPREsperion Therapeutics, Inc. | COM | 5,791,594 | $12.9M | 2.5% | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 1,149,406 | $7.83M | 1.5% | History |
| PBYIPuma Biotechnology, Inc. | COM | 1,486,544 | $4.85M | 0.9% | History |
| KYTXKyverna Therapeutics, Inc. | COM | 499,152 | $3.74M | 0.7% | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 134,612 | $3.16M | 0.6% | History |
| ANABAnaptysbio, Inc | COM | 25,000 | $626.5K | 0.1% | History |
| LXRXLexicon Pharmaceuticals, Inc. | COM NEW | 30,000 | $50.4K | <0.1% | History |